Education
About Us
Working with TipRanks
Follow Us
Abcellera Biologics, Inc. (ABCL)
:ABCL
ABCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.89 - $4.34
Previous CloseN/A
Volume1.71M
Average Volume (3M)3.96M
Market Cap
$774.77M
Enterprise Value$279.22M
Total Cash (Recent Filing)$386.54M
Total Debt (Recent Filing)$82.26M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 08, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding297,987,670
10 Day Avg. Volume4,508,919
30 Day Avg. Volume3,960,512
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.75
Price to Cash Flow (P/CF)-6.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.68
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$11.40Price Target Upside350.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
AbCellera Biologics News
PremiumCompany Announcements
AbCellera Biologics’ Earnings Call: Transition Amid Challenges
PremiumCompany Announcements
AbCellera Biologics Reports 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial StrategyABCL is leveraging its large $800M+ liquidity position to cultivate an internal pipeline and high-value strategic partnerships.
Research And DevelopmentTransition from platform to pipeline continues with two significant therapeutic antibodies entering clinical trials.
Strategic PartnershipsAbCellera succeeded in signing two new partnerships in 2024, with Biogen and venture firms Viking and ArrowMark, and expanding two legacy programs.
Bears Say
Financial PerformanceRevenues came in below estimates.
Impairment ChargesThe wide EPS miss was largely due to a $32M non-cash R&D impairment charge related to a discontinued transgenic technology.
Revenue TrendsPartner research fees drove Q4 topline revenues lower, though management expects research fees will continue to trend lower over time.
---
Ownership Overview
43.24% Insiders
2.88% Mutual Funds
0.24% Other Institutional Investors
52.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $1.89 and its highest was $4.34 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $774.77M.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on Feb 27, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.013.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 297,987,670 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went down -11.644%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
---
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.40 (350.59% Upside)
$11.40 (350.59% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 155.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $940.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.33%
12-Months-Change
Fundamentals
Return on Equity
-14.75%
Trailing 12-Months
Asset Growth
-8.57%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
---
ABCL Company Deck
---
ABCL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights AbCellera's successful transition to a clinical stage biotech with strong liquidity and strategic advancements in key programs and partnerships. However, the company faced challenges with declining revenue and a significant net loss, driven by high R&D expenses and reduced partnership activities.Read More>---
ABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
ABCL Stock 12 Month Forecast
Average Price Target
$11.40
▲(350.59% Upside)
Technical Analysis
Gyre Therapeutics
―
Xeris Pharmaceuticals
―
CureVac
―
Praxis Precision Medicines
―
Pharvaris
―
Best Analysts Covering ABCL
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-24.09%
reiterated a buy rating 10 days ago
Copying Scott Schoenhaus's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -24.09% per trade.
---